T1	intervention 68 77	tamoxifen
T2	control 81 91	raloxifene
T3	eligibility 681 711	high-risk postmenopausal women
T5	total-participants 757 763	19,747
T6	location 813 826	North America
T11	intervention-participants 1670 1673	973
T12	control-participants 1695 1699	1010
T13	total-participants 1232 1236	1983
T14	outcome 1716 1731	Sexual function
T15	control-participants 1914 1918	9769
T17	intervention-participants 2021 2025	9743
T18	outcome 2053 2077	musculoskeletal problems
T19	outcome 2104 2115	dyspareunia
T20	outcome 2144 2155	weight gain
T21	iv-cont-mean 2079 2083	1.15
T22	cv-cont-mean 2087 2091	1.10
T23	iv-cont-mean 2117 2121	0.78
T24	cv-cont-mean 2125 2129	0.68
T25	iv-cont-mean 2157 2161	0.82
T26	cv-cont-mean 2165 2169	0.76
T28	outcome 2299 2317	vasomotor symptoms
T29	outcome 2342 2352	leg cramps
T30	outcome 2381 2405	bladder control symptoms
T31	iv-cont-mean 2276 2280	0.29
T32	cv-cont-mean 2284 2288	0.19
T33	iv-cont-mean 2319 2323	0.96
T34	cv-cont-mean 2327 2331	0.85
T35	iv-cont-mean 2354 2358	1.10
T36	cv-cont-mean 2362 2366	0.91
T37	iv-cont-mean 2407 2411	0.88
T38	cv-cont-mean 2415 2419	0.73
T39	outcome 2512 2588	patient-reported outcomes for physical health, mental health, and depression
T4	outcome 1960 1981	mean symptom severity
T10	outcome 2635 2650	sexual function
T16	outcome 2226 2274	mean symptom severity for gynecological problems
T7	outcome-Measure 1442 1462	SF-36 physical (PCS)
T8	outcome-Measure 1467 1499	mental (MCS) component summaries
